Sarepta Therapeutics Inc $ 87.06 1.81 (2.12%)
Volume:
1,474,709
Avg Vol (1m):
2,586,929
Market Cap $:
6.87 Bil
Enterprise Value $:
5.82 Bil
PE Ratio:
0.00
PB Ratio:
7.66
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.36 | ||
| Equity-to-Asset | 0.32 | ||
| Debt-to-Equity | 0.86 | ||
| Debt-to-EBITDA | -1.49 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 1.21 | ||
| Beneish M-Score | -3.44 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -123.95 | ||
| Net Margin % | -121.3 | ||
| ROE % | -61.36 | ||
| ROA % | -24.74 | ||
| ROC (Joel Greenblatt) % | -202.89 | ||
| 3-Year Revenue Growth Rate | 259.9 | ||
| 3-Year EBITDA Growth Rate | -18.5 | ||
| 3-Year EPS without NRI Growth Rate | -20.9 |
SRPT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 7.66 | ||
| PS Ratio | 13.55 | ||
| Price-to-Free-Cash-Flow | 135.61 | ||
| Price-to-Operating-Cash-Flow | 54.31 | ||
| EV-to-EBIT | -10.59 | ||
| EV-to-EBITDA | -11.25 | ||
| EV-to-Revenue | 11.76 | ||
| Current Ratio | 6.14 | ||
| Quick Ratio | 5.56 | ||
| Days Inventory | 1175.69 | ||
| Days Sales Outstanding | 77.04 | ||
| Days Payable | 481.08 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 7.78 | ||
| Price-to-Median-PS-Value | 0.44 | ||
| Earnings Yield (Greenblatt) % | -9.44 |